(Q53421812)

English

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

scientific article published on 17 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Giulia Taraboletti

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Raffaella Giavazzi

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Alessandra Decio

object named as

Alessandra Decio

1

0 references

object named as

Dorina Belotti

8

0 references

object named as

Paolo Ubezio

6

0 references

author name string

Marta Cesca

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Francesca Bizzaro

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Luca Porcu

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Rossana Bettolini

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

publication date

17 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Clinical & Experimental Metastasis

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

32

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

647-658

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Guidelines for the welfare and use of animals in cancer research

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Antiangiogenic therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Targeted anti-vascular therapies for ovarian cancer: current evidence

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Better therapeutic trials in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

The biology of ovarian cancer: new opportunities for translation

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Tumor heterogeneity in the clinic: is it a real problem?

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Is VEGF a predictive biomarker to anti-angiogenic therapy?

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Tumor macroenvironment and metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Patient-derived tumour xenografts as models for oncology drug development

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Past, present, and future challenges in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Examining the utility of patient-derived xenograft mouse models

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9734-1

21 January 2018

Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26185056

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10585-015-9734-1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26185056

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53421812&oldid=2212118318"